Inhaltsbereich
| 52 Einträge | 1, 2, 3 › » |
Seite 1 / 3
 Druckansicht
|
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. |
| Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ |
| The Lancet. Oncology. 2015 Dec 5. pii: S1470-2045(15)00464-7. doi: 10.1016/S1470-2045(15)00464-7 |
| PMID: 26671818 |
| Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. |
| Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA |
| Leukemia. 2016 Aug 5. pii: leu2016186. doi: 10.1038/leu.2016.186 |
| PMID: 27491641 |
| Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. |
| Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R |
| Leukemia. 2016 Dec 27. pii: leu2016390. doi: 10.1038/leu.2016.390 |
| PMID: 28025582 |
| Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. |
| Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D |
| Leukemia & lymphoma. 2017 Mar 17. doi: 10.1080/10428194.2017.1298755 |
| PMID: 28306371 |
| Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. |
| Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P |
| The Lancet. Oncology. 2017 Aug 23. pii: S1470-2045(17)30578-8. doi: 10.1016/S1470-2045(17)30578-8 |
| PMID: 28843768 |
| Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. |
| Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA |
| Leukemia & lymphoma. 2017 Sep 22. doi: 10.1080/10428194.2017.1376743 |
| PMID: 28937327 |
| The Genomic Footprints of the Fall and Recovery of the Crested Ibis. |
| Feng S, Fang Q, Barnett R, Li C, Han S, Kuhlwilm M, Zhou L, Pan H, Deng Y, Chen G, Gamauf A, Woog F, Prys-Jones R, Marques-Bonet T, Gilbert MTP, Zhang G |
| Current biology : CB. 2019 Jan 10. pii: S0960-9822(18)31609-9. doi: 10.1016/j.cub.2018.12.008. pmc: PMC6345625 |
| PMID: 30639104 |
| Evolutionary History, Genomic Adaptation to Toxic Diet, and Extinction of the Carolina Parakeet. |
| Gelabert P, Sandoval-Velasco M, Serres A, de Manuel M, Renom P, Margaryan A, Stiller J, de-Dios T, Fang Q, Feng S, Mañosa S, Pacheco G, Ferrando-Bernal M, Shi G, Hao F, Chen X, Petersen B, Olsen RA, Navarro A, Deng Y, Dalén L, Marquès-Bonet T, Zhang G, Antunes A, Gilbert MTP, Lalueza-Fox C |
| Current biology : CB. 2019 Dec 12. pii: S0960-9822(19)31438-1. doi: 10.1016/j.cub.2019.10.066 |
| PMID: 31839456 |
| A new duck genome reveals conserved and convergently evolved chromosome architectures of birds and mammals. |
| Li J, Zhang J, Liu J, Zhou Y, Cai C, Xu L, Dai X, Feng S, Guo C, Rao J, Wei K, Jarvis ED, Jiang Y, Zhou Z, Zhang G, Zhou Q |
| GigaScience. pii: 6039068. doi: 10.1093/gigascience/giaa142 |
| PMID: 33406261 |
| A new emu genome illuminates the evolution of genome configuration and nuclear architecture of avian chromosomes. |
| Liu J, Wang Z, Li J, Xu L, Liu J, Feng S, Guo C, Chen S, Ren Z, Rao J, Wei K, Chen Y, Jarvis ED, Zhang G, Zhou Q |
| Genome research. 2021 Jan 6. pii: gr.271569.120. doi: 10.1101/gr.271569.120 |
| PMID: 33408157 |
| Phylogeny and sex chromosome evolution of palaeognathae. |
| Wang Z, Zhang J, Xu X, Witt C, Deng Y, Chen G, Meng G, Feng S, Xu L, Szekely T, Zhang G, Zhou Q |
| Journal of genetics and genomics = Yi chuan xue bao. 2021 Jul 13. pii: S1673-8527(21)00199-5. doi: 10.1016/j.jgg.2021.06.013 |
| PMID: 34872841 |
| Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection. |
| Romeike M, Spach S, Huber M, Feng S, Vainorius G, Elling U, Versteeg GA, Buecker C |
| EMBO reports. 2022 Jul 19. doi: 10.15252/embr.202255375 |
| PMID: 35852463 |
| Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. |
| Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L |
| British journal of haematology. 2015 Jul 7. doi: 10.1111/bjh.13582 |
| PMID: 26153365 |
| The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. |
| Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A |
| European journal of cancer (Oxford, England : 1990). 2015 May 11. pii: S0959-8049(15)00373-1. doi: 10.1016/j.ejca.2015.04.017 |
| PMID: 25976743 |
| Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. |
| Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep 17. pii: mdu456. doi: 10.1093/annonc/mdu456 |
| PMID: 25231953 |
| YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. |
| Taniguchi K, Moroishi T, de Jong PR, Krawczyk M, Grebbin BM, Luo H, Xu RH, Golob-Schwarzl N, Schweiger C, Wang K, Di Caro G, Feng Y, Fearon ER, Raz E, Kenner L, Farin HF, Guan KL, Haybaeck J, Datz C, Zhang K, Karin M |
| Proceedings of the National Academy of Sciences of the United States of America. 2017 Jan 27. pii: 1620290114. doi: 10.1073/pnas.1620290114 |
| PMID: 28130546 |
| Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. |
| Noguchi S, Pritchard KI, Burris HA, Rugo HS, Gnant M, Hortobagyi GN, Latini L, Yardley DA, Melichar B, Petrakova K, Harb W, Feng W, Cahana A, Taran T, Campone M, Baselga J, Sahmoud T, Lebwohl DE, Piccart-Gebhart MJ |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.99 |
| PMID: 28146687 |
| Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. |
| Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A |
| European urology. 2017 Jun 24. pii: S0302-2838(17)30497-9. doi: 10.1016/j.eururo.2017.06.002 |
| PMID: 28655541 |
| Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. |
| Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM |
| Molecular cancer research : MCR. 2018 Feb 16. pii: 1541-7786.MCR-17-0539. doi: 10.1158/1541-7786.MCR-17-0539 |
| PMID: 29453313 |
| Cerebral serotonin transporter measurements with [C]DASB: A review on acquisition and preprocessing across 21 PET centres. |
| Nørgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, Lubberink M, Parsey RV, Politis M, Rabiner EA, Slifstein M, Sossi V, Suhara T, Talbot PS, Turkheimer F, Strother SC, Knudsen GM |
| Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2018 Jan 1. doi: 10.1177/0271678X18770107 |
| PMID: 29651896 |
| 52 Einträge | 1, 2, 3 › » |
Seite 1 / 3
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
